Diabetes News

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according to a presentation at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

In 2020 — the last year of the study period — researchers estimated that one in 10 new cases of type 2 diabetes mellitus could be connected to the intake of sugar-sweetened beverages.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau, according to a presentation.

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with cardiometabolic syndrome at baseline, a speaker reported.

Treatment with metformin plus glyburide was not noninferior to insulin alone in preventing large for gestational age infants born from pregnant women with gestational diabetes, according to trial results published in JAMA.

AI has shown promise for remote patient monitoring and alerting providers in ICUs, but still has limitations as a clinical tool in pediatrics.

Among patients with endogenous hypercortisolism, relacorilant improved cardiometabolic parameters such as blood pressure, HbA1c and weight, according to results of a long-term extension study.

New guidance on GLP-1 receptor agonist use, how to tackle medication shortages and expanded continuous glucose monitoring use for type 2 diabetes are among the updates in the American Diabetes Association’s 2025 Standards of Care.

In patients with hypercortisolism and difficult-to-control type 2 diabetes, mifepristone lowered HbA1c at 24 weeks compared with placebo, researchers reported at World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.